The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback